| Prev Close | 0.00 |
| Day Low/High | 0.00 / 0.00 |
| 52 Wk Low/High | 0.00 / 0.00 |
| Exchange | OTC BB |
| Div & Yield | N.A. (N.A) |
Nichi-Iko Pharmaceutical Co., Ltd.
The generic-drug industry has undergone a flurry of acquisition activity over the past 18 months, highlighted by the long-anticipated but only recent closing of Teva Pharmaceutical's purchase of Allergan's generics.
Shepard Vision, Inc., a Delaware corporation (the "Purchaser") and a wholly-owned subsidiary of Nichi-Iko Pharmaceutical Co.
The most recent short interest data has been released for the 07/15/2016 settlement date, which shows a 791,641 share decrease in total short interest for Sagent Pharmaceuticals Inc , to 1,570,672, a decrease of 33.51% since 06/30/2016. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Sagent Pharmaceuticals, Inc.
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Sagent...
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Sagent Pharmaceuticals, Inc.
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Sagent Pharmaceuticals, Inc.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AMRC, ATTO, CODI, PEB, SGNT, TCRD, TEO, TSLX, USBI, VMI Downgrades: EMXX Initiations: AEUA, CABO Read on to get TheStreet Quant Ratings' detailed report:
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Sagent...
Sagent Pharmaceuticals (SGNT) stock closed sharply higher today after agreeing to be purchased by Nichi-Iko for $736 million.
These three stocks are seeing big trading volume today, but that doesn't necessarily mean you want to buy them.
Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Sagent...
Nichi-Iko Pharmaceutical Co., Ltd (TSE:4541) and Sagent Pharmaceuticals, Inc.
Products Include Propofol for the U.S. Market; Positive Next Step in 'Triple E' Growth Strategy
Trade-Ideas LLC identified Sagent Pharmaceuticals (SGNT) as a strong on high relative volume candidate
Investors considering a purchase of Sagent Pharmaceuticals Inc stock, but tentative about paying the going market price of $13.94/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $10 strike, which has a bid at the time of this writing of 45 cents.
Newly Created Position Supports Long-Term Growth Strategy to Expand Product Offerings
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.
Investors eyeing a purchase of Sagent Pharmaceuticals Inc shares, but tentative about paying the going market price of $13.96/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the October put at the $10 strike, which has a bid at the time of this writing of 55 cents.
Newly Created Position Supports Long-Term Growth Strategy to Expand Product Offerings and Enhance Operational Performance
